Weill Cornell Medicine is a school as part of a university.
JNJ-42165279 is a drug developed by Janssen Pharmaceutica which acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase -LRB- FAAH -RRB- , with an IC50 of 70 nM .. Janssen Pharmaceutica. Janssen Pharmaceutica. fatty acid amide hydrolase. fatty acid amide hydrolase. It is described as a covalently binding but slowly reversible selective inhibitor of FAAH .. JNJ-42165279 is being developed for the treatment of anxiety disorders and major depressive disorder .. major depressive disorder. major depressive disorder. Clinical development has progressed as far as Phase II human trials with two studies in patients with mood disorders registered in ClinicalTrials.gov .. trials. clinical trial. ClinicalTrials.gov. ClinicalTrials.gov. In early 2016 , a trial with a different FAAH inhibitor -- Bial 's BIA 10-2474 -- resulted in a series of severe adverse events , including a death .. Bial. Bial. BIA 10-2474. BIA 10-2474. In response , Janssen announced that it was temporarily suspending dosing in its two Phase II clinical trials with JNJ-42165279 , describing the decision as `` precautionary measure follows safety issue with different drug in class '' .. trials. clinical trial. Janssen was emphatic that no serious adverse events had been reported in any of the clinical trials with JNJ-42165279 to date .. trials. clinical trial. The suspension is to remain in effect until more information is available about the BIA 10-2474 study .. BIA 10-2474. BIA 10-2474